Key Highlights

  • Net loss per share was USD 0.81 against an estimate of USD 0.94; net loss was USD 46.6 million.
  • License Revenue was USD 1.21 million against USD 0.396 million last year and an estimate of USD 460,930.
  • Research and development expense was USD 45.6 million against USD 32.5 million; general and administrative expense was USD 14.1 million.
  • Cash and equivalents were USD 55.7 million, alongside USD 782.1 million of short-term and USD 406.0 million of long-term investments.

What does a clinical-stage antibody developer report after a quarter of trial starts and fresh financing? For Dianthus Therapeutics, Inc. (NASDAQ:DNTH), the answer is a net loss of USD 46.6 million, or USD 0.81 per share, against an estimate of a USD 0.94 loss, and license revenue of USD 1.21 million. A year earlier the net loss was USD 36.8 million and license revenue was USD 0.396 million.

Claseprubart Across Three Neurology Trials

The lead candidate, claseprubart, is a subcutaneous antibody that selectively inhibits active C1s. In chronic inflammatory demyelinating polyneuropathy (CIDP), the company reported a 75% response rate in the interim analysis of the first 40 participants completing Part A of the Phase 3 CAPTIVATE trial, against a target of 50% or greater. In November 2026 it announced that the trial is now projected to need fewer than 200 participants in Part A to randomize 128 responders into Part B. Top-line Part A results are scheduled by the end of 2027 and Part B results by the end of 2028.

In generalized myasthenia gravis, the company announced the start of the Phase 3 EMERGE trial in about 195 participants in June 2026, with top-line results scheduled for the second half of 2028. Enrollment in the Phase 2 MoMeNtum trial in multifocal motor neuropathy was completed in August with 46 patients, above the target of 36, and top-line results are scheduled for December 2026. A Phase 3 trial in that indication is planned to start in 2027.

Bifunctional Fusion Proteins Behind the Lead Program

A fusion protein licensed from Nanjing Leads Biolabs in October 2025 targets BDCA2 and BAFF/APRIL. The company prioritized Sjögren's disease, lupus and dermatomyositis. Dosing of lupus patients in Part B of a Phase 1 study in China began in October 2026, volunteer data are scheduled for the first quarter of 2027 and preliminary lupus data for the second half of 2027. A multiple-ascending dose study outside China is planned for the second quarter of 2027.

An internally developed fusion protein combining claseprubart and TACI is preclinical, and the company aims for Phase 1 readiness by year end 2027.

Spending, Financing and the Balance Sheet

Research and development expense was USD 45.6 million against USD 32.5 million, and general and administrative expense was USD 14.1 million against USD 8.2 million, for operating expenses of USD 59.7 million. Interest and investment income was USD 12.1 million against USD 3.7 million. Nine-month net loss was USD 137.7 million against USD 97.9 million.

For the nine months, Operating Activities used USD 128.2 million, and financing provided USD 857.3 million. The company sold 3,632,534 shares under its first at-the-market agreement for gross proceeds of USD 200.0 million, and on September 18, 2026 entered a new agreement for up to USD 500 million, under which no sales had been made. Management said existing cash and investments fund obligations for at least twelve months and that it may need additional capital.

Figures Worth Comparing

A loss of USD 0.81 per share sits alongside Research and Development spending of USD 45.6 million, cash and cash equivalents of USD 55.7 million and investments totaling USD 782.1 million short term and USD 406.0 million long term. License revenue of USD 1.21 million stems from the Tenacia license agreement, which carries development milestones of up to USD 15.0 million.

Management named MoMeNtum top-line results in December 2026, fusion protein volunteer data in the first quarter of 2027, a Phase 3 start in MMN in 2027, and CAPTIVATE Part A results by the end of 2027 as the dated items ahead.